Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Regulatory applications accepted in the U.S. and Japan for Breyanzi (lisocabtagene maraleucel) in relapsed or refractory follicular lymphoma and relapsed or refractory mantle cell lymphoma – BMS

Written by | 9 Feb 2024

Bristol Myers Squibb announced three regulatory acceptances from the FDA and Japan’s Ministry of Health, Labour and Welfare (MHLW) for Breyanzi (lisocabtagene maraleucel) In the U.S., the FDA… read more.

Updated data from the phase 1/II BRUIN trial of Jaypirca in patients with covalent BTK inhibitor pre-treated r/r Mantle Cell Lymphoma continue to demonstrate durable efficacy – Eli Lilly

Written by | 5 Jun 2023

A poster presentation (Abstract #7514) presented at ASCO will highlight efficacy data with a median survival follow-up time of two years for Jaypirca in relapsed or refractory MCL… read more.

Improved treatment emerges for mantle cell lymphoma

Written by | 25 Jun 2022

Addition of ibrutinib to standard chemotherapy for patients over 65 with previously untreated mantle cell lymphoma (MCL) has led to significantly improved progression-free survival, researchers reported on June… read more.

Health Canada approves Brukinsa to treat Mantle Cell Lymphoma – BeiGene

Written by | 4 Aug 2021

BeiGene, Ltd. a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced that Brukinsa (zanubrutinib) has… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.